$2.8 Million NIH Grant Received by Children's Hospital of Philadelphia.

Juvent's Dynamic Motion Therapy([R] )Selected for Clinical Study to Evaluate Its Effect on the Bone Loss Experienced by Children with Crohn's Disease

SOMERSET, N.J. -- Juvent, Inc., a leading developer of non-invasive, therapeutic medical devices utilizing Dynamic Motion Therapy([R]) (DMT) technology, announced today that the National Institutes of Health has awarded a grant of approximately $2.8 million to The Children's Hospital of Philadelphia (CHOP) to fund a clinical study of the effect of Juvent' DMT technology upon the bone loss experienced by children with Crohn's disease. Children's Hospital pediatric nephrologist Mary B. Leonard, M.D. will serve as the study's Principal Investigator.

The 12-month, double-blind, placebo-controlled, randomized trial will evaluate the effect of daily 10 minute treatments with DMT technology as an anabolic bone stimulus in 159 children with Crohn's disease. The trial will be followed by a 12-month open-label phase to provide all subjects with access to DMT.

Children with Crohn's disease have significant deficits in tibia and spine bone mineral density (BMD). The primary aim of this study will be to determine if treatment with the DMT technology results in increased tibia and spine BMD in children with Crohn's disease. Secondary analyses will examine (1) the effect of the therapy on the functional muscle-bone unit, (2) the impact of pubertal stage, physical activity, and disease characteristics on the response to the therapy, and (3) the sensitivity of traditional dual energy x-ray absorptiometry (DEXA) measures of BMD to treatment effects.

Juvent, Inc. is a medical device development company that has commercialized a patented Dynamic Motion Therapy technology. Based on several years of pre-clinical and pilot clinical studies, Juvent believes its DMT technology, utilizing low-level mechanical signals to prevent bone loss as well as rebuild lost bone, will become the preferred therapy for control and reversal of osteoporosis and other diseases involving bone loss. For more information, visit http://www.juvent.com

The Children's Hospital of Philadelphia was founded in 1855 as the nation's first pediatric hospital. Through its long-standing commitment to providing exceptional patient care, training new generations of pediatric healthcare professionals and pioneering major research initiatives, Children's Hospital has fostered many discoveries that have benefited children worldwide. Its pediatric research program is among the largest in the country, ranking third in National Institutes of Health funding. In addition, its unique family-centered care and public service programs have brought the 430-bed hospital recognition as a leading advocate for children and adolescents. For more information, visit http://www.chop.edu.

This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential or financial performance. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. Juvent, Inc. undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Forward-looking statements in this press release should be evaluated together with the many uncertainties that affect Juvent, Inc.'s business.

Dynamic Motion Therapy [R] is a registered trademark of Juvent, Inc.